昆明医学院学报2001，Vol.22Issue(1)：9-13,5.
白血病MICM分型的临床和实验研究
Study on MICM Classification on Clinical
and Experiment of Leukemia
李正发 1沈晓梅 1王云娟 1朱宝生 2欧阳红梅 3甸自金3
作者信息
- 1. 云南省第一人民医院血液科
- 2. 云南省第一人民医院细胞遗传室,
- 3. 云南省第一人民医院血液细胞室
- 折叠
摘要
Abstract
To explore the relations of Morphology Immnuophe-notype Cytogenetics Molecular biology(MICM) detection on diagnosis andtreat,emt of leukemia． Methods: 68 cases of leukemia patients had beenanalyzed by morphology(FAB)． Immunohistochemistry(Flow Cytometry, FCM)． chromosome G banding technique and dual-color fluorescence insitu hybridization (D-FISH)．Technique:All patients were treated bychemotherapy． T test and X2 test of significance． Results: 7 cases have acute leukema aberration antigen expression． 5 out of 47 cases acutemyeliod leukemia patients accompany lymhocytic interrelated antigenexpression． 2/l5 cases acute lymphoid leukemia accompany myelocyteinterrelated antigen expression． 2 cases acute lmphoid leukemia are T cell and B cell interrelated antigen mingle expression． had been examined46,XY,t(8,2l) translocation of chromosome and bcr/abl fusion genes inthe acute leukemia patients． 16 out of 20 chronic myeloid leukemia patientshad philadelphia chromosome． 7 out of 20 patients had complicate karyotype． 5 out of 20 patients had bcr/abl fusion gene, l out of 4 patient had bcr/abl fusion gene that Ph chro mosome showed negative in CML． 3/4 cases patients had complicate chromosome． The ratio of CR use l time chemotherapy and the total ratio of CR using 2 times chemotherapywith aberration antigen expression in acute leukemia was significantly lessthan those of the acute leukemia patient had single system antigenexpression(P<0.05)． The time of CML-BC with complicate c hromosome karyotype was significantly short than those of Ph showed negative in CML(P<0.05)． Conclusion: The MICM classification is more acc urate for diagnosis of leukemia and more significant in guiding the leukemiatreamen．关键词
白血病/MICM分型/诊断/治疗分类
医药卫生引用本文复制引用
李正发,沈晓梅,王云娟,朱宝生,欧阳红梅,甸自金..白血病MICM分型的临床和实验研究[J].昆明医学院学报,2001,22(1):9-13,5.
